The stock of Stellar Biotechnologies Inc (NASDAQ:SBOT) hit a new 52-week low and has $1.76 target or 13.00% below today’s $2.02 share price. The 7 months bearish chart indicates high risk for the $20.37 million company. The 1-year low was reported on Nov, 21 by Barchart.com. If the $1.76 price target is reached, the company will be worth $2.65 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 54,829 shares traded hands or 59.68% up from the average. Stellar Biotechnologies Inc (NASDAQ:SBOT) has declined 51.81% since April 19, 2016 and is downtrending. It has underperformed by 55.67% the S&P500.
Analysts await Stellar Biotechnologies Inc (NASDAQ:SBOT) to report earnings on December, 12. They expect $-0.14 earnings per share, up 26.32% or $0.05 from last year’s $-0.19 per share. After $-0.14 actual earnings per share reported by Stellar Biotechnologies Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
According to Zacks Investment Research, “Stellar Biotechnologies, Inc. is engaged in the development, manufacture and commercialization of keyhole limpet hemocyanin and technologies. The Company’s principle products consist of: stellar KLH protein and stellar KLH ELISA Kits. KLH is a component for cancer vaccines and anticipated therapeutic vaccines, including those for lymphoma, sarcoma, small cell lung cancer, Alzheimer’s disease, rheumatoid arthritis, lupus and Post Traumatic Stress Disorder chemical dependencies. It operates primarily in the United States, Europe, and Asia. Stellar Biotechnologies, Inc. is headquartered in Port Hueneme, California.”
More recent Stellar Biotechnologies Inc (NASDAQ:SBOT) news were published by: Marketwatch.com which released: “Stellar Biotechnologies stock price target cut to $7 from $17 at Maxim Group” on November 05, 2015. Also Seekingalpha.com published the news titled: “Stellar Biotechnologies: Vaccine Tech Buoyed By Partnerships” on June 23, 2016. Barrons.com‘s news article titled: “Stellar Biotechnologies Gets a Positive Sign” with publication date: February 25, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.